SCHEMBL7651469

SCHEMBL7651469

O=S(=O)(CCCN1CCc2ccccc2C1)c1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 11/20 0.63
HTR1A P08908 6/20 0.63
DRD2 P14416 6/20 0.63
HTR2A P28223 6/20 0.63
DRD3 P35462 6/20 0.63
HTR2B P41595 6/20 0.63
HRH1 P35367 3/20 0.63
SLC6A4 P31645 1/20 0.63
HTR5A P47898 1/20 0.60
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648778 0.91 KDM4E (0.53) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL7647774 0.88 HTR7 (0.55) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL7651640 0.85 HTR7 (0.54) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL7648765 0.84 ALDH1A1 (0.54) HTR7HTR1AHTR2AMEN1KMT2A
SCHEMBL10035542 0.81 HTR7 (0.82) HTR7HTR1ADRD2HTR2ADRD3
Hydrochloric Acid SCHEMBL2136791 0.81 HTR7 (0.80) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL8979922 0.81 HTR7 (0.82) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL7647665 0.80 HTR7 (0.52) HTR7HTR1ADRD2HTR2ADRD3
SCHEMBL8980036 0.80 HTR7 (0.80) HTR7HTR1ADRD2HTR2ADRD3
Hydrochloric Acid SCHEMBL4228329 0.80 HTR7 (0.80) HTR7HTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US claimed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US disclosed
WO-2000000472-A1 5-HT7 RECEPTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A HTR7 1/4885HTR1A 3/4885DRD2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.